Kitov Pharmaceuticals Holdings (NASDAQ: KTOV) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Volatility and Risk
Kitov Pharmaceuticals Holdings has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 2.49, indicating that its stock price is 149% more volatile than the S&P 500.
This table compares Kitov Pharmaceuticals Holdings and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kitov Pharmaceuticals Holdings||N/A||N/A||N/A|
This is a breakdown of recent ratings and price targets for Kitov Pharmaceuticals Holdings and Aurinia Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kitov Pharmaceuticals Holdings||0||0||0||0||N/A|
Aurinia Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 107.97%. Given Aurinia Pharmaceuticals’ higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Kitov Pharmaceuticals Holdings.
Valuation and Earnings
This table compares Kitov Pharmaceuticals Holdings and Aurinia Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Kitov Pharmaceuticals Holdings||N/A||N/A||-$12.12 million||N/A||N/A|
|Aurinia Pharmaceuticals||$170,000.00||2,835.45||-$23.29 million||($1.37)||-4.21|
Kitov Pharmaceuticals Holdings has higher revenue, but lower earnings than Aurinia Pharmaceuticals.
Insider and Institutional Ownership
5.4% of Kitov Pharmaceuticals Holdings shares are owned by institutional investors. Comparatively, 27.7% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.0% of Kitov Pharmaceuticals Holdings shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Kitov Pharmaceuticals Holdings beats Aurinia Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Kitov Pharmaceuticals Holdings Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.